She has been diagnosed by one doctor with Myasthenia gravis; This spontaneous case was reported by a consumer and describes the occurrence of MYASTHENIA GRAVIS (She has been diagnosed by one doctor with Myasthenia gravis) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027C21A and 046B21A) for COVID-19 vaccination.     Patient was not allergic to medications, food and other products.    On 23-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYASTHENIA GRAVIS (She has been diagnosed by one doctor with Myasthenia gravis) (seriousness criterion medically significant). At the time of the report, MYASTHENIA GRAVIS (She has been diagnosed by one doctor with Myasthenia gravis) was resolving.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided. Patient experienced symptoms such as vision issue, double vision, droopy eye (Ptosis), focusing problems, it take a while for patient to focus. Patient first had trouble seeing, if she raised the eyes up she'd see blurry, then she was able to see with one eye then the ptosis happened, if she straighten her vision she can see straight but as soon as she sees up, right, left or down she sees double, patient states she feels like her symptoms are constantly transforming.  COVID test was not performed.  Patient status on improvement or worsening reported as, originally it was really bad, now she only has the double vision and focusing problem. No vaccines given within 1 month prior to Moderna COVID-19 vaccine. Patient has visit various doctors, Patient was referred to specialists and she had an appointment with a neurologist in July. The patient stated that she was having too many issues so did not get the booster doses as she did not know what the booster dose was going to do. Treatment medication was reported as no.  Company Comment:  This spontaneous case concerns a 43-year-old female patient with no medical history reported, who experienced the unexpected serious (medically significant) adverse event of special interest Myasthenia gravis, that occurred on an unknown date after receiving the second dose of mRNA-1273 vaccine (Latency between vaccine and event cannot be established).  Patient developed eye problems characterized by double vision, blurred vision, and drooping of eyelid for which a diagnosis of Myasthenia gravis was given by one of the doctors consulted.  No treatment or laboratory tests were reported. Patient received the first dose of mRNA-1273 vaccine 28 days prior to current mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 29-Apr-2022: Follow-up Dose Information updated and event verbatim added.; Sender's Comments: This spontaneous case concerns a 43-year-old female patient with no medical history reported, who experienced the unexpected serious (medically significant) adverse event of special interest Myasthenia gravis, that occurred on an unknown date after receiving the second dose of mRNA-1273 vaccine (Latency between vaccine and event cannot be established).  Patient developed eye problems characterized by double vision, blurred vision, and drooping of eyelid for which a diagnosis of Myasthenia gravis was given by one of the doctors consulted.  No treatment or laboratory tests were reported. Patient received the first dose of mRNA-1273 vaccine 28 days prior to current mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.